Whole Genome Sequencing: Nako- Pais, Prof. Annette Peters, Germany

justlxsa

Senior Member (Voting Rights)

27 Million€ for a new study within the National Decade against Post- Infectious Diseseases.

Not much info yet.

“The aim of this project is to expand the NAKO database for future research on post-infectious diseases on three levels: First, information on the genome (whole genome) and a broad range of antibodies against relevant infectious disease pathogens will be generated from 25,000 NAKO participants without PE. These can serve as a population-based reference group in future research projects to compare profiles of patients from other studies with those of healthy individuals. Second, the genome and antibodies of approximately 20,000 NAKO participants with confirmed PE or ME/CFS will be determined to improve the medical data on patients. Third, 4,250 PE patients and 4,250 non-patients will undergo comprehensive molecular characterization for a case-control study: This will include genome and antibody analyses, autoantibody determinations, and other laboratory analyses at various molecular levels. The data generated in the project will be made available for research into post-infectious diseases via a secure data processing environment.”
 
This is fantastic, wow. Really impressive!

But if I understand correctly, the study isn't focused specifically on ME/CFS, but on post-infectious illnesses more broadly. So I imagine it could include Lyme disease and other conditions, right? And Long Covid as well?

Will they divide patients into different groups according to their diagnoses and conditions? How exactly is the study going to work?
 
This is fantastic, wow. Really impressive!

But if I understand correctly, the study isn't focused specifically on ME/CFS, but on post-infectious illnesses more broadly. So I imagine it could include Lyme disease and other conditions, right? And Long Covid as well?

Will they divide patients into different groups according to their diagnoses and conditions? How exactly is the study going to work?
In the German version it says “PE bzw. ME/CFS” which suggests that it could be only ME/CFS.

but we will have to see and wait for more info, they could also include LongCovid for example.
 
If all of this is confirmed, this is absolutely huge news, potentially even revolutionary for ME/CFS research. Really.

With SequenceME and the other ongoing research projects, I genuinely think we could finally start getting some real answers about our disease by 2028, provided everything goes well and the results live up to expectations.

It's enough to give us a little hope again, despite everything. Fingers crossed that all this is confirmed and that these projects deliver on their promise.
 
That's a lot of money!

Immediate thoughts: 1) It looks like they are going to sequence 45,000 people total-ish? And then on top of that do other antibody screening? I don't think this budget can afford long read WGS for that, so I'm guessing this is short read sequencing. Which would mean no structural variant calling or variants in complex regions which sequenceME will have.

2) Where have they found 20,000 PVF or ME/CFS patients from? Even decode couldn't manage to do that with very extensive campaigning. The UK biobank has a couple of thousand or something or so and their diagnostic validity is uncertain.
 
Machine translation:

NAKO-PAIS - Expansion of the NAKO Health Study Database for Research on Post-Infectious Diseases

Grant number:01GG2601
Grant amount:27,840,696 EUR
Funding period:2026 - 2028
Project lead:Prof. Dr. Annette Peters
Address:NAKO e.V.
Am Taubenfeld 21/2
69123 Heidelberg

Post-infectious diseases (PIDs) can occur after various infections and affect millions of people worldwide. The most well-known are Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). These conditions are highly complex and affect various organ systems. They can massively restrict the quality of life of those affected. PIDs represent a challenge for modern medicine. Due to a lack of knowledge regarding the causes and mechanisms of these diseases, they are currently neither effectively treatable nor curable in their chronic stage.

The National Decade against Post-Infectious Diseases is therefore intended to establish a long-term research strategy to systematically investigate causes, mechanisms, diagnostics, therapy, and prevention approaches—with the goal of improving the outlook for patients. As an initial measure, the data basis for research, based on existing patient cohorts of the NAKO Health Study (NAKO) and the Network for University Medicine (NUM), is to be improved.

The objective of the present project is to expand the NAKO database for future research on post-infectious diseases on three levels: First, genomic information (whole genome) and a broad range of antibodies against relevant pathogens of infectious diseases are to be generated for 25,000 NAKO participants without PIDs. These can serve as a population-based reference group in future research projects to compare profiles of affected individuals from other studies with the profiles of healthy individuals. Second, genomes and antibodies are to be determined for approximately 20,000 NAKO participants with confirmed PID or ME/CFS to improve the medical data basis regarding affected individuals. Third, 4,250 individuals with PID and 4,250 non-affected individuals are to be comprehensively characterized molecularly for a case-control study: Genomic and antibody analyses, as well as autoantibody determinations and further laboratory analyses on various molecular levels, are planned. The data generated in the project are to be made available for research on post-infectious diseases via a secure data processing environment.
 
2) Where have they found 20,000 PVF or ME/CFS patients from? Even decode couldn't manage to do that with very extensive campaigning. The UK biobank has a couple of thousand or something or so and their diagnostic validity is uncertain.
But we did manage that. In DecodeME, 26k completed the questionnaire and 21k met study criteria, so given that the total population of Germany is at least 12 million more than in the UK it doesn't not seem impossible to me.

Of the 18K sample kits returned we got just under 16k useable samples so perhaps that is what you were thinking of.
 
Immediate thoughts: 1) It looks like they are going to sequence 45,000 people total-ish? And then on top of that do other antibody screening? I don't think this budget can afford long read WGS for that, so I'm guessing this is short read sequencing. Which would mean no structural variant calling or variants in complex regions which sequenceME will have.
NAKO already has started WGS sequencing from what I understand, so possibly long read WGS might be feasible?

2) Where have they found 20,000 PVF or ME/CFS patients from? Even decode couldn't manage to do that with very extensive campaigning. The UK biobank has a couple of thousand or something or so and their diagnostic validity is uncertain.
I think Germany's equivalent to the biobank would maybe be the NAKO and from what I've gathered the lead PI on this project, was also the lead PI on the EpiPAIS project which wanted to survey the NAKO participants this year. But I agree 20,000 seems to ambitious when the cohort consists of only 200 000, so either it's a mess or they need additional recruiting.

I think it would be good if there was more cooperation and exchange of ideas between the UK and Germany in this area.
 
But we did manage that. In DecodeME, 26k completed the questionnaire and 21k met study criteria, so given that the total population of Germany is at least 12 million more than in the UK it doesn't not seem impossible to me.

Of the 18K sample kits returned we got just under 16k useable samples so perhaps that is what you were thinking of.

Yeah if they're going to recruit this cohort via a campaign like decode did then it sounds doable - just reading that paragraph it read a bit to me like this was a cohort that already existed like the uk biobank, let's wait to get more info. Yes I'm referring to the bottom numbers you mention there.

NAKO already has started WGS sequencing from what I understand, so possibly long read WGS might be feasible?

That would be good if so, if part of it is already done or has supplementary funding from elsewhere! I was just going on what seems possible based on that amount of funding and the numbers they've given alone. I could be wrong of course.
 
This has been the no-brained project from the start. And only 5 % of the total budget. What great news! I hope they share lots of details about everything and are as rigorous as the DecodeME team.
Project lead: Prof. Dr. Annette Peters
Bio
Population-based cohort studies
• Health impacts of air pollution and other environmental factors
• Interaction of genetics, epigenetics and the environment
• Chronic diseases such as diabetes, CVD, lung disease and new approaches to define intermediate phenotypes
• Age-related multimorbidity
Bio
Annette Peters leads the population-based KORA cohort initiated in Augsburg, Germany, which has followed 18,000 individuals with regular follow-up since the mid-1980s. She also plays a leading role in the German National Cohort NAKO, which prospectively investigates 205,000 men and women since 2014. NAKO is a nationwide, beyond the state-of-the-art, large- scale epidemiological study that includes innovative biobanking for all members and magnet resonance tomography assessments for 30,000 participants.
As principal investigator, Annette Peters is responsible for the NAKO study center in Augsburg and the central biorepository at Helmholtz Munich. She chaired the NAKO board of directors until 2022, and will resume this role in 2025. During the COVID-19 pandemic, she started additional data collection to help understand the health impact of the COVID-19 pandemic.
 
the only thing that doesn’t add up is that 20.000 Nako patients with Postinfectious Diseases are to be included, but Nako only is a cohort of 205.000 people -who they follow since 2014.

10% of the whole cohort having *confirmed* PAIS/ ME/CFS is impossible.
 
the only thing that doesn’t add up is that 20.000 Nako patients with Postinfectious Diseases are to be included, but Nako only is a cohort of 205.000 people -who they follow since 2014.

10% of the whole cohort having *confirmed* PAIS/ ME/CFS is impossible.
Do you think they are adding 20,000 new PAIS/MECFS patients to this cohort of 205,000?
 
Back
Top Bottom